Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for Louise Gardner�
33.70
+0.53 (1.60%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.68 - 33.82
52 week 31.34 - 39.95
Open 33.40
Vol / Avg. 291,407.00/857,589.00
Mkt cap 2.30B
P/E 26.89
Div/yield     -
EPS 1.25
Shares 69.45M
Beta 0.42
Inst. own 137%
Aug 10, 2015
Q4 2015 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 9, 2015
Myriad Genetics Inc at Goldman Sachs Healthcare Conference
May 5, 2015
Q3 2015 Myriad Genetics Inc Earnings Call - Webcast
May 5, 2015
Q3 2015 Myriad Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 11.93% 22.64%
Operating margin 19.86% 35.27%
EBITD margin - 37.04%
Return on average assets 11.04% 21.65%
Return on average equity 12.64% 24.35%
Employees 1,649 -
CDP Score - -

Address

320 Wakara Way
SALT LAKE CITY, UT 84108
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Peter Durkee Meldrum President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 82
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Jayne B. Hart Executive Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 58
Bio & Compensation  - Reuters
Ronald S. Rogers Executive Vice President - Corporate Communications
Age: 46
Bio & Compensation  - Reuters
Robert Gardner Harrison Chief Information Officer
Age: 48
Bio & Compensation  - Reuters
Jerry S. Lanchbury Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters